Cargando…
922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506496/ http://dx.doi.org/10.1016/j.annonc.2020.08.1037 |
| _version_ | 1783585030850740224 |
|---|---|
| author | Forster, M. Metcalf, R. Sacco, J. Kong, A. Wheeler, G. Forsyth, S. Bhat, R. Blair, K. Ward, J. Lowe, H. Spanswick, V. Ensell, L. Hartley, J. White, L. |
| author_facet | Forster, M. Metcalf, R. Sacco, J. Kong, A. Wheeler, G. Forsyth, S. Bhat, R. Blair, K. Ward, J. Lowe, H. Spanswick, V. Ensell, L. Hartley, J. White, L. |
| author_sort | Forster, M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7506496 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75064962020-09-23 922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas Forster, M. Metcalf, R. Sacco, J. Kong, A. Wheeler, G. Forsyth, S. Bhat, R. Blair, K. Ward, J. Lowe, H. Spanswick, V. Ensell, L. Hartley, J. White, L. Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2020-09 2020-09-22 /pmc/articles/PMC7506496/ http://dx.doi.org/10.1016/j.annonc.2020.08.1037 Text en Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Forster, M. Metcalf, R. Sacco, J. Kong, A. Wheeler, G. Forsyth, S. Bhat, R. Blair, K. Ward, J. Lowe, H. Spanswick, V. Ensell, L. Hartley, J. White, L. 922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas |
| title | 922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas |
| title_full | 922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas |
| title_fullStr | 922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas |
| title_full_unstemmed | 922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas |
| title_short | 922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas |
| title_sort | 922p each: a phase ii study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506496/ http://dx.doi.org/10.1016/j.annonc.2020.08.1037 |
| work_keys_str_mv | AT forsterm 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas AT metcalfr 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas AT saccoj 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas AT konga 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas AT wheelerg 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas AT forsyths 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas AT bhatr 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas AT blairk 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas AT wardj 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas AT loweh 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas AT spanswickv 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas AT enselll 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas AT hartleyj 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas AT whitel 922peachaphaseiistudyevaluatingthesafetyandantitumouractivityofavelumabandcetuximabinrecurrentmetastaticsquamouscellcarcinomas |